JP2017532374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532374A5 JP2017532374A5 JP2017535609A JP2017535609A JP2017532374A5 JP 2017532374 A5 JP2017532374 A5 JP 2017532374A5 JP 2017535609 A JP2017535609 A JP 2017535609A JP 2017535609 A JP2017535609 A JP 2017535609A JP 2017532374 A5 JP2017532374 A5 JP 2017532374A5
- Authority
- JP
- Japan
- Prior art keywords
- mannitol
- pharmaceutical composition
- eutectic
- item
- cyclobenzaprine hcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000594 mannitol Substances 0.000 claims description 45
- 229930195725 Mannitol Natural products 0.000 claims description 37
- 235000010355 mannitol Nutrition 0.000 claims description 37
- 229960003572 cyclobenzaprine Drugs 0.000 claims description 36
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims description 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000005496 eutectics Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000005550 wet granulation Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000155 melt Substances 0.000 claims description 6
- 239000002610 basifying agent Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940058023 trisodium citrate anhydrous Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 description 5
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052238P | 2014-09-18 | 2014-09-18 | |
| US62/052,238 | 2014-09-18 | ||
| PCT/US2015/051068 WO2016044796A1 (en) | 2014-09-18 | 2015-09-18 | Eutectic formulations of cyclobenzaprine hydrochloride |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018173466A Division JP6717902B6 (ja) | 2014-09-18 | 2018-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532374A JP2017532374A (ja) | 2017-11-02 |
| JP2017532374A5 true JP2017532374A5 (https=) | 2018-11-01 |
| JP6614724B2 JP6614724B2 (ja) | 2019-12-04 |
Family
ID=55533932
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535609A Active JP6614724B2 (ja) | 2014-09-18 | 2015-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2018173466A Active JP6717902B6 (ja) | 2014-09-18 | 2018-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2019236602A Withdrawn JP2020059757A (ja) | 2014-09-18 | 2019-12-26 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2021169539A Withdrawn JP2022001605A (ja) | 2014-09-18 | 2021-10-15 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2023116057A Withdrawn JP2023126486A (ja) | 2014-09-18 | 2023-07-14 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2025076812A Pending JP2025107355A (ja) | 2014-09-18 | 2025-05-02 | シクロベンザプリン塩酸塩の共融製剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018173466A Active JP6717902B6 (ja) | 2014-09-18 | 2018-09-18 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2019236602A Withdrawn JP2020059757A (ja) | 2014-09-18 | 2019-12-26 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2021169539A Withdrawn JP2022001605A (ja) | 2014-09-18 | 2021-10-15 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2023116057A Withdrawn JP2023126486A (ja) | 2014-09-18 | 2023-07-14 | シクロベンザプリン塩酸塩の共融製剤 |
| JP2025076812A Pending JP2025107355A (ja) | 2014-09-18 | 2025-05-02 | シクロベンザプリン塩酸塩の共融製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10357465B2 (https=) |
| EP (1) | EP3193854A4 (https=) |
| JP (6) | JP6614724B2 (https=) |
| CN (2) | CN112618494B (https=) |
| AU (2) | AU2015317336B2 (https=) |
| BR (1) | BR112017005231A2 (https=) |
| IL (2) | IL251218B (https=) |
| MX (1) | MX387402B (https=) |
| MY (1) | MY186047A (https=) |
| SG (2) | SG10201902203VA (https=) |
| WO (1) | WO2016044796A1 (https=) |
| ZA (1) | ZA201701637B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700578T1 (it) | 2009-11-20 | 2018-01-11 | Tonix Pharma Holdings Ltd | Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| SMT202400324T1 (it) | 2013-03-15 | 2024-11-15 | Tonix Pharma Ltd | Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo |
| MY186047A (en) | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
| MX2020006140A (es) | 2017-12-11 | 2020-08-13 | Tonix Pharma Holdings Ltd | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. |
| US20220117915A1 (en) * | 2018-08-20 | 2022-04-21 | Tonix Pharma Holdings Limited | Methods of treating acute stress disorder and posttraumatic stress disorder |
| NL2023661B1 (en) * | 2019-08-19 | 2021-04-21 | Seranovo Holding B V | Pharmaceutical Eutectic Salt Formulation |
| AU2021253592A1 (en) | 2020-04-08 | 2022-11-10 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| MX2023005899A (es) * | 2020-11-20 | 2023-08-16 | TONIX Pharmaceuticals Holding Corp | Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol. |
| US20240024256A1 (en) * | 2020-12-07 | 2024-01-25 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for fibromyalgia |
| WO2023059728A1 (en) * | 2021-10-06 | 2023-04-13 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| CA3260042A1 (en) | 2022-06-21 | 2023-12-28 | Tonix Pharmaceuticals Holding Corp. | CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF A (SARS)-COV-2 (PASC) INFECTION |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| NZ262679A (en) | 1993-02-22 | 1997-08-22 | Vivorx Pharmaceuticals Inc | Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| US20030077227A1 (en) | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| PT1077683E (pt) | 1998-05-14 | 2003-04-30 | Alza Corp | Terapia anti-depressiva |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| BR0013017A (pt) | 1999-08-13 | 2002-04-16 | Vela Pharmaceuticals Inc | Usos de composições para o tratamento ou prevenção dos distúrbios do sono usando doses muito baixas de ciclobenzaprina |
| AR025111A1 (es) | 1999-08-13 | 2002-11-06 | Janus Pharmaceuticals Inc | Metodos y composiciones para tratar trastornos de ansiedad generalizada |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2001089476A1 (en) | 2000-05-19 | 2001-11-29 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| DE60231896D1 (de) | 2001-11-05 | 2009-05-20 | Krele Pharmaceuticals Llc | Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus |
| US7659253B2 (en) | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7700561B2 (en) | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7105486B2 (en) | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| JP4288263B2 (ja) | 2002-10-25 | 2009-07-01 | コレジウム ファーマシューティカル， インク． | ｐ−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法 |
| CA2509365C (en) | 2002-12-09 | 2012-08-07 | American Bioscience, Inc. | Compositions and methods of delivery of pharmacological agents |
| SI1644019T2 (en) | 2003-05-29 | 2018-04-30 | Shire Llc | Abuse resistant amphetamine compounds |
| JP2007510642A (ja) | 2003-11-03 | 2007-04-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬 |
| US20050143350A1 (en) | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US9682043B2 (en) | 2003-12-09 | 2017-06-20 | Medcrystalforms, Llc | Method of preparation of mixed phase co-crystals with active agents |
| EP1715853A4 (en) | 2004-02-17 | 2012-07-18 | Transcept Pharmaceuticals Inc | COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20070196364A1 (en) * | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| US7532935B2 (en) | 2005-07-29 | 2009-05-12 | Cyberonics, Inc. | Selective neurostimulation for treating mood disorders |
| US7994220B2 (en) | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| US20080146672A1 (en) | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
| EP2170064A4 (en) | 2007-06-22 | 2010-08-04 | Merck Sharp & Dohme | 6,5-pyrrolopiperidine tachykinin receptor antagonists |
| SG183069A1 (en) | 2007-07-23 | 2012-08-30 | Synosia Therapeutics | Treatment of post-traumatic stress disorder |
| US20090060983A1 (en) | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| US20100247649A1 (en) | 2007-10-30 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| US20090148532A1 (en) | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| US9314469B2 (en) | 2008-05-05 | 2016-04-19 | Tonix Pharma Holdings Limited | Method for treating neurocognitive dysfunction |
| JP5380909B2 (ja) | 2008-05-30 | 2014-01-08 | 株式会社ブリヂストン | 金型及び樹脂発泡成形品の成形方法 |
| US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| EP2233134A1 (en) | 2009-03-27 | 2010-09-29 | McNeil AB | Multi-portion intra-oral dosage form with organoleptic properties |
| US20100247586A1 (en) | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| US8784781B2 (en) | 2009-09-24 | 2014-07-22 | Mcneil-Ppc, Inc. | Manufacture of chewing gum product with radiofrequency |
| SMT201700578T1 (it) | 2009-11-20 | 2018-01-11 | Tonix Pharma Holdings Ltd | Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US20130165511A1 (en) | 2010-09-01 | 2013-06-27 | TONIX Pharmaceuticals Holding Corp | Treatment for cocaine addiction |
| US11998516B2 (en) * | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| RS63822B1 (sr) | 2012-06-15 | 2023-01-31 | Tonix Pharma Holdings Ltd | Kompozicije i postupci za transmukoznu apsorpciju |
| SMT202400324T1 (it) | 2013-03-15 | 2024-11-15 | Tonix Pharma Ltd | Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo |
| MY186047A (en) * | 2014-09-18 | 2021-06-17 | Tonix Pharma Holdings Ltd | Eutectic formulations of cyclobenzaprine hydrochloride |
-
2015
- 2015-09-18 MY MYPI2017700889A patent/MY186047A/en unknown
- 2015-09-18 SG SG10201902203VA patent/SG10201902203VA/en unknown
- 2015-09-18 WO PCT/US2015/051068 patent/WO2016044796A1/en not_active Ceased
- 2015-09-18 EP EP15841528.1A patent/EP3193854A4/en active Pending
- 2015-09-18 CN CN202011576351.9A patent/CN112618494B/zh active Active
- 2015-09-18 SG SG11201701995PA patent/SG11201701995PA/en unknown
- 2015-09-18 CN CN201580050140.2A patent/CN107072968B/zh active Active
- 2015-09-18 MX MX2017003644A patent/MX387402B/es unknown
- 2015-09-18 JP JP2017535609A patent/JP6614724B2/ja active Active
- 2015-09-18 AU AU2015317336A patent/AU2015317336B2/en active Active
- 2015-09-18 US US15/511,287 patent/US10357465B2/en active Active
- 2015-09-18 BR BR112017005231A patent/BR112017005231A2/pt not_active Application Discontinuation
-
2017
- 2017-03-07 ZA ZA2017/01637A patent/ZA201701637B/en unknown
- 2017-03-16 IL IL251218A patent/IL251218B/en active IP Right Grant
-
2018
- 2018-09-18 JP JP2018173466A patent/JP6717902B6/ja active Active
-
2019
- 2019-07-22 US US16/518,338 patent/US11026898B2/en active Active
- 2019-12-26 JP JP2019236602A patent/JP2020059757A/ja not_active Withdrawn
-
2020
- 2020-10-05 IL IL277814A patent/IL277814B/en unknown
- 2020-12-17 AU AU2020289838A patent/AU2020289838B2/en active Active
-
2021
- 2021-10-15 JP JP2021169539A patent/JP2022001605A/ja not_active Withdrawn
-
2023
- 2023-07-14 JP JP2023116057A patent/JP2023126486A/ja not_active Withdrawn
-
2025
- 2025-05-02 JP JP2025076812A patent/JP2025107355A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532374A5 (https=) | ||
| CN101622302B (zh) | 生产喷雾干燥产品的制剂工艺方法 | |
| RU2597790C2 (ru) | Способ обработки частиц активных фармацевтических ингредиентов | |
| Chang et al. | Anti-hygroscopic effect of leucine on spray-dried herbal extract powders | |
| JP2021522248A5 (https=) | ||
| MA38397A1 (fr) | Agglomérats inhalables de particules de support poreuses et médicament micronisé | |
| JP2018537565A (ja) | 表面反応炭酸カルシウムを含む細粒の製造方法 | |
| JP2004523594A5 (https=) | ||
| JP2009530271A5 (https=) | ||
| JP2005508977A (ja) | 医薬品化合物中の熱分解法シリカに基づく粒体材料の使用 | |
| JP2022532431A5 (https=) | ||
| RU2016142819A (ru) | Твердая композиция, содержащая аморфный софосбувир | |
| CN102861106A (zh) | 一种复方氨酚烷胺微丸的制备方法 | |
| RU2018144108A (ru) | Никотиносодержащие частицы | |
| JP2012509922A5 (https=) | ||
| JP2013523676A5 (https=) | ||
| RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
| HRP20161624T1 (hr) | Produkt ko-mikronizacije koji sadrži ulipristal acetat | |
| CN103948933A (zh) | 一种白藜芦醇包合物及其制剂的制备方法 | |
| US20260114496A1 (en) | Nicotine-containing agglomerates and methods of forming the same | |
| JP2022528570A5 (https=) | ||
| CN102772392B (zh) | 一种阿比多尔缓控释胶囊及其制备方法 | |
| CN103891786A (zh) | 一种驱蚊喷雾剂及其制备方法 | |
| CN102145017B (zh) | 改善中药提取液喷雾干燥过程中热熔型粘壁的方法 | |
| CN101954104A (zh) | 一种丹皮酚固体分散体空气清新剂 |